ferric reductase Inhibitors
1 drugsAbout ferric reductase
Ferric reductase is an enzyme that reduces ferric iron (Fe3+) to ferrous iron (Fe2+), which is essential for iron absorption, transport, and utilization within the body.
Ferric reductase represents a potential drug target due to its role in iron metabolism, but currently there is no genetic evidence directly linking it to specific diseases.
There is one FDA-approved drug, AURYXIA, a small molecule targeting ferric reductase, marketed by KERYX BIOPHARMS for 'other' therapeutic areas since 2014.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
Top ferric reductase Drugs
KERYX BIOPHARMS is the only company with an approved drug targeting ferric reductase.
Low competition suggests potential for market entry, but also indicates higher risk.
ferric reductase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ferric reductase, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches.
ferric reductase Clinical Trials 24 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 2 | 0 | 1 | 100% |
| Phase 3 | 14 | 11 | 1 | 1 | 92% |
| Phase 4 | 6 | 4 | 1 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ferric reductase Drug Approval Timeline (2014 - 2014)
AURYXIA was first approved in 2014 and remains the only approved drug.
The stagnant approval timeline suggests market saturation or challenges in target validation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 28 clinical trials targeting ferric reductase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities